Lantern Pharma Inc. Debt Securities, Available-for-sale, Amortized Cost
Lantern Pharma Inc. (LTRN) had Debt Securities, Available-for-sale, Amortized Cost of $19.93 million as of 2023-12-31, per its 10-K filed 2024-03-18.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2024-03-18
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost $19.93M.
- 2023-09-30: Debt Securities, Available-for-sale, Amortized Cost $20.17M.
- 2023-06-30: Debt Securities, Available-for-sale, Amortized Cost $20.39M.
- 2023-03-31: Debt Securities, Available-for-sale, Amortized Cost $19.93M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2023-12-31 | $19.93M 10-K · filed 2024-03-18 |
| 2023-09-30 | $20.17M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $20.39M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $19.93M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $18.96M 10-K · filed 2024-03-18 |
| 2021-12-31 | $19.37M 10-K · filed 2023-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |